Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy.
Therapeutic use of interferon-alpha (IFN-alpha) has been associated with the development of a variety of autoimmune disorders. We describe a patient who received chronic treatment with IFN-alpha following autologous bone marrow transplantation for multiple myeloma. The patient developed an antibody inhibitor directed against factor VIII coagulant protein (FVIIIC) leading to a fatal hemorrhagic diathesis. The association between IFN-alpha therapy and autoimmune complications deserves wider recognition and further study.
Stricker
R B
RB
Department of Medicine, California Pacific Medical Center, San Francisco.
Barlogie
B
B
Kiprov
D D
DD
D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000209:etiology; D016026:Bone Marrow Transplantation; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery / Q000628:therapy
D001323:Autoantibodies; D016898:Interferon-alpha; D005169:Factor VIII